A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies

Protocol No

BEIGENE-BGB-11417-103

Phase

I/II

Summary

This project is being done to look at the safety and tolerability of an investigational anticancer drug, currently known as BGB-11417, when given in combination with azacitidine.

Description

A Phase 1b/2 Study of BGB-11417 in Patients with Myeloid Malignancies

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL